These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19963374)

  • 21. Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
    Shah U; Lankin CM; Boyle CD; Chackalamannil S; Greenlee WJ; Neustadt BR; Cohen-Williams ME; Higgins GA; Ng K; Varty GB; Zhang H; Lachowicz JE
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4204-9. PubMed ID: 18558486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
    Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
    J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
    Matthews JM; Hoekstra WJ; Dyatkin AB; Hecker LR; Hlasta DJ; Poulter BL; Andrade-Gordon P; de Garavilla L; Demarest KT; Ericson E; Gunnet JW; Hageman W; Look R; Moore JB; Reynolds CH; Maryanoff BE
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2747-52. PubMed ID: 15125926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-peptide oxytocin agonists.
    Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
    Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
    Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala.
    Huber D; Veinante P; Stoop R
    Science; 2005 Apr; 308(5719):245-8. PubMed ID: 15821089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement.
    Moss N; Xiong Z; Burke M; Cogan D; Gao DA; Haverty K; Heim-Riether A; Hickey ER; Nagaraja R; Netherton M; O'Shea K; Ramsden P; Schwartz R; Shih DT; Ward Y; Young E; Zhang Q
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7189-93. PubMed ID: 23084902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel pyrrolidine heterocycles as CCR1 antagonists.
    Merritt JR; James R; Paradkar VM; Zhang C; Liu R; Liu J; Jacob B; Chiriac C; Ohlmeyer MJ; Quadros E; Wines P; Postelnek J; Hicks CM; Chen W; Kimble EF; O'Brien L; White N; Desai H; Appell KC; Webb ML
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5477-9. PubMed ID: 20708929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
    Chini B; Manning M; Guillon G
    Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral oxytocin antagonists.
    Borthwick AD
    J Med Chem; 2010 Sep; 53(18):6525-38. PubMed ID: 20550119
    [No Abstract]   [Full Text] [Related]  

  • 34. Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction.
    Buettelmann B; Ballard TM; Gasser R; Fischer H; Hernandez MC; Knoflach F; Knust H; Stadler H; Thomas AW; Trube G
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5958-61. PubMed ID: 19740657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations.
    Moulin A; Demange L; Ryan J; Mousseaux D; Sanchez P; Bergé G; Gagne D; Perrissoud D; Locatelli V; Torsello A; Galleyrand JC; Fehrentz JA; Martinez J
    J Med Chem; 2008 Feb; 51(3):689-93. PubMed ID: 18193826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
    Catarzi D; Colotta V; Varano F; Calabri FR; Filacchioni G; Galli A; Costagli C; Carlà V
    J Med Chem; 2004 Jan; 47(1):262-72. PubMed ID: 14695840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
    Shah U; Boyle CD; Chackalamannil S; Neustadt BR; Lindo N; Greenlee WJ; Foster C; Arik L; Zhai Y; Ng K; Wang S; Monopoli A; Lachowicz JE
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4199-203. PubMed ID: 18562199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
    Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
    J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
    Xu Y; Mayhugh D; Saeed A; Wang X; Thompson RC; Dominianni SJ; Kauffman RF; Singh J; Bean JS; Bensch WR; Barr RJ; Osborne J; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Huang N; Luffer-Atlas D; Rungta D; Maise DE; Mantlo NB
    J Med Chem; 2003 Nov; 46(24):5121-4. PubMed ID: 14613314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.